MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation

Starting soon · Phase 3

Conditions studied: Atrial Flutter With Rapid Ventricular Response

In brief

The purpose of this research study is to find out if the use of magnesium in addition to Metoprolol, a rate controlling medication that you would be offered in the Emergency Department today unrelated to this study, will help reduce your high heart rate (rapid ventricular response).

Key facts

Study ID

NCT07632157

Run by

Wake Forest University Health Sciences

People needed

196

Starts

2026-10-01

Expected to finish

2028-12-01

Last updated by the study team

2026-06-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years or older
• Able to provide informed consent
• Primary diagnosis atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR) greater than or equal to 120 beats per minute
• Metoprolol as rate control agent
• English speaking

You may not qualify if…

• Hemodynamically unstable patients (SBP <90, MAP <65)
• Impaired consciousness
• Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
• Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
• Rhythms other than atrial fibrillation, such as sick sinus syndrome or wide-complex ventricular response
• Acute myocardial infarction
• Contraindications to magnesium sulfate (including myasthenia gravis)
• Allergy or sensitivity to any study drugs
• Previously enrolled in this trial during a different patient encounter
• Withdrew from study

Where it is running

• Advocate Christ Medical Center Emergency Department (ACMC ED) — Oak Lawn, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.